Cisplatin
Platinol · Platinum agent
Proximal tubular ATN + magnesium wasting; the archetype.
ATNLYTEPRE
SevereOpen →
Bone-seeking radiopharmaceutical (153Sm-EDTMP)
Samarium-153 lexidronam
Quadramet · Sm-153
Bone-seeking radiopharmaceutical for painful osteoblastic metastases; renally excreted with dominant myelosuppression and caution in renal impairment.
Moderateestablished · approved 1997
Palliation of pain from osteoblastic skeletal metastases (e.g., prostate, breast, and other cancers) that are avid on bone scintigraphy
Signature kidney injury
Acute Tubular Necrosis
Clinically meaningful nephrotoxicity is uncommon; the dominant and dose-limiting toxicity is reversible myelosuppression. No reliable drug-specific AKI incidence is established. Renal caution stems from renal/urinary excretion of the unbound radiopharmaceutical.
Source: Dolezal et al., Vnitr Lek 2003 (myelosuppression-dominant); renal events uncommon
Mechanism of kidney injury
The agent and its non-bone-bound fraction are cleared by the kidneys and excreted in urine, so impaired renal function can prolong circulation, increase marrow radiation exposure, and theoretically deliver radiation to renal/urinary tract tissue. Direct renal injury is not a prominent clinical feature; the principal radiation toxicity is to bone marrow. Electrolyte shifts can accompany the underlying malignancy and supportive care.
Clinical presentation
Predominantly hematologic: transient leukopenia and thrombocytopenia nadiring around 3-4 weeks with subsequent recovery. Renal manifestations are uncommon; when renal function is impaired, expect heightened/prolonged myelosuppression rather than a distinct nephropathy.
Onset
Myelosuppression nadirs within weeks; recovery typically over the following weeks.
Reversibility
Reversible
Anticancer mechanism
Samarium-153 lexidronam (153Sm-EDTMP) couples the beta-/gamma-emitting radionuclide samarium-153 to the bone-avid chelator ethylenediaminetetramethylene phosphonic acid (EDTMP). It concentrates in regions of high osteoblastic activity at metastatic sites, delivering localized beta radiation for pain palliation rather than curative cytoreduction.
Management
Largely supportive: monitor and manage cytopenias (transfusion, growth factors as indicated). For any AKI, ensure volume status, relieve urinary obstruction, and provide standard renal support; dialysis is supportive rather than a defined removal strategy.
Risk factors
- Pre-existing renal impairment (delayed clearance, increased marrow exposure)
- Compromised bone marrow reserve / prior myelosuppressive therapy
- Inadequate hydration at administration
- Urinary retention/obstruction increasing tract radiation exposure
Prevention
- Ensure adequate hydration before and after administration to promote urinary clearance
- Encourage frequent voiding to limit bladder radiation; manage incontinence/retention
- Assess renal function and marrow reserve before dosing
- Radiation-safety handling of urine per nuclear-medicine protocols
Note · The renal angle is the renal/urinary excretion route warranting caution, not a frequent direct nephrotoxic lesion; the dominant toxicity is mild, temporary myelosuppression.
Clinical depth
Renal dose adjustment
Renal impairment reduces clearance and increases marrow radiation exposure; administer with caution and assess renal function before dosing. Follow product labeling/nuclear-medicine guidance for impaired renal function.
Dialyzability & ESKD dosing
Not established as a removal modality; clinical role of dialysis is supportive only.
Differential diagnosis
Differentiate transient radiopharmaceutical myelosuppression from disease- or other-therapy-related cytopenias; distinguish any AKI from tumor-related obstructive uropathy, hypercalcemia of malignancy, or volume depletion rather than a primary radiopharmaceutical nephropathy.
Monitoring
- CBC with platelets (weekly, through nadir and recovery)
- Renal function/eGFR before administration
- Hydration and urinary output
- Radiation-safety monitoring of excreta per protocol
Key trials & series
- Pain-palliation efficacy and tolerability shown in 153Sm-EDTMP series (e.g., PMID 24681187, PMID 12728593), with myelosuppression as the dominant, reversible toxicity and no significant hematologic worsening signal in reported cohorts.
Clinical pearls
- 153Sm-EDTMP is renally excreted — hydrate and ensure good urine flow, and respect radiation-safety handling of urine.
- Myelosuppression, not nephrotoxicity, is the dose-limiting toxicity; check the CBC, not just the creatinine.
- Renal impairment chiefly matters because delayed clearance increases marrow radiation exposure.
Where it strikes
Nephron segments
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
Tubular Lumen
The urine flow path
Interstitium
Supporting tissue around the tubules
Injury signatures
Acute Tubular NecrosisElectrolyte Wasting
Evidence
3 peer-reviewed references. Citation metadata via PubMed / NLM.
PMID[Myelotoxicity after systemic radionuclide therapy of painful bone metastases with 153Samarium-EDTMP].Dolezal J et al. · Vnitr Lek 2003 · PMID 12728593Characterizes the dominant, mild and reversible myelosuppression of 153Sm-EDTMP across 57 patients, framing the kidney as a secondary consideration via excretion/clearance.PMID(153)Sm-EDTMP for pain relief of bone metastases from prostate and breast cancer and other malignancies.Correa-Gonzalez L et al. · Arch Med Res 2014 · PMID 24681187Large palliation series (277 patients) confirming safety/tolerability with stable hematologic parameters, supporting a kidney-cautious but not overtly nephrotoxic profile.PMIDFormulation, preclinical evaluation, and preliminary clinical investigation of an in-house freeze-dried EDTMP kit suitable for the preparation of 177Lu-EDTMP.Das T et al. · Cancer Biother Radiopharm 2014 · PMID 25409337EDTMP radiopharmaceutical with Quadramet-identical composition showing skeletal uptake with major renal clearance, documenting the renal excretion route relevant to Sm-153-EDTMP caution.